DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07374445

CompletedPhase 4

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

The Timing for Liraglutide in Patients Remaining Obese at 6 Months After Metabolic Surgery: an Observational Study

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

100

actual

Study population

Bariatric Surgery, Obesity / overweight

Key I/E criterion

•BMI ≥28

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07374445
Org study ID2023-507-02

Timeline

Milestones

Study start2023-09-01actual
Primary completion2025-06-01actual
Study completion2025-06-01actual
Study first posted2026-01-28actual
Last update posted2026-01-28actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Bariatric SurgeryObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients 6 months after metabolic surgery;
•18 years ≤ age ≤ 65 years;
•Body Mass Index (BMI) ≥ 28 kg/m^2

Exclusion criteria

•allergy to liraglutide, severe hepatic or renal impairment (eGFR <60 mL/min/1.73 m² or ALT/AST ≥3× ULN)
•history of medullary thyroid carcinoma, MEN-2 or other malignancies
•pancreatitis or severe gastrointestinal disease, pregnancy or lactation
•use of anti-obesity drugs or other interventional trials within 3 months or major uncontrolled illness
•Patients were discontinued if withdrawn, intolerant, lost to follow-up, or developed severe adverse events.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
3
Glycemic / diabetes
2
Cardiometabolic biomarkers
1

Weight & body composition

3 endpoints
Primary/protocol endpoint

Change in %TWL from baseline to endpoint across patient groups

Time frame:48 weeks from enrollment

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change in BMI from baseline to endpoint across patient groups

Time frame:48 weeks from enrollment

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change in body composition from baseline to endpoint across patient groups

Time frame:48 weeks from enrollment

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint

Changes in fasting blood glucose from baseline to endpoint

Time frame:48 weeks from enrollment

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in HbA1c from baseline to endpoint across patient groups

Time frame:48 weeks from enrollment

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Changes in blood pressure from baseline to endpoint

Time frame:48 weeks from enrollment

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.